Sai Life Sciences IPO is a book-built issue with a total size of ₹3,042.62 crores. It includes a fresh issue of 1.73 crore shares worth ₹950 crores and an offer for sale (OFS) of 3.81 crore shares amounting to ₹2,092.62 crores.
The IPO will open for subscription on December 11, 2024, and close on December 13, 2024. The allotment of shares is scheduled to be finalized on December 16, 2024, and the company is expected to list on the BSE and NSE on December 18, 2024.
The price band for the IPO is set between ₹522 and ₹549 per share. Retail investors can apply for a minimum lot of 27 shares, which requires an investment of ₹14,823. For small Non-Institutional Investors (sNII), the minimum investment is ₹207,522 for 14 lots (378 shares), while big Non-Institutional Investors (bNII) will need ₹1,007,964 for 68 lots (1,836 shares). With a mix of fresh equity and OFS, this IPO offers a significant opportunity for investors across different categories.
Sai Life Sciences IPO Details
| IPO Open Date: | December 11, 2024 |
| IPO Close Date: | December 13, 2024 |
| Face Value: | ₹1 Per Equity Share |
| IPO Price Band: | ₹522 to ₹549 Per Share |
| Issue Size: | Approx ₹3,042.62 Crores |
| Fresh Issue: | Approx ₹950.00 Crores |
| Offer for Sale: | Approx 38,116,934 Equity Shares |
| Issue Type: | Book Built Issue |
| IPO Listing: | BSE & NSE |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
Sai Life Sciences IPO Timeline
Sai Life Sciences IPO opens on December 11, 2024, and closes on December 13, 2024.
| IPO Open Date | Wednesday, December 11, 2024 |
| IPO Close Date | Friday, December 13, 2024 |
| Basis of Allotment | Monday, December 16, 2024 |
| Initiation of Refunds | Tuesday, December 17, 2024 |
| Credit of Shares to Demat | Tuesday, December 17, 2024 |
| Listing Date | Wednesday, December 18, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on December 13, 2024 |
Sai Life Sciences IPO Lot Size
Investors can bid for a minimum of 27 shares and in multiples thereof. The table below depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amounts.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 27 | ₹14,823 |
| Retail (Max) | 13 | 351 | ₹192,699 |
| S-HNI (Min) | 14 | 378 | ₹207,522 |
| S-HNI (Max) | 67 | 1,809 | ₹993,141 |
| B-HNI (Min) | 68 | 1,836 | ₹1,007,964 |
About Sai Life Sciences Limited
Sai Life Sciences is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) that has established itself as a prominent player in the pharmaceutical sector. Founded in 1999, the company has grown rapidly over 25 years, emerging as one of the fastest-growing CRDMOs among listed Indian peers.
The company primarily supports pharmaceutical and biotech innovators by accelerating the discovery, development, and commercialization of complex small molecules.
Sai Life Sciences offers end-to-end drug discovery services, from target identification and validation to Investigational New Drug (IND) applications. Its expertise spans medicinal chemistry, biology, drug metabolism, pharmacokinetics (DMPK), toxicology, and cGMP manufacturing.
Sai Life Sciences operates globally, with advanced facilities in India, the UK, and the USA. The company employs over 2,845 people, including 290+ PhDs and 1,691 postgraduates, as of March 2024. This highly skilled team enables the company to address complex scientific challenges and deliver exceptional results to its clients.
The company has made significant investments in state-of-the-art infrastructure. Its research facilities cover 200,000 square feet of process R&D lab space, and its manufacturing sites offer a combined capacity of over 180 cubic meters. These facilities support the production of key starting materials (KSMs), cGMP intermediates, and active pharmaceutical ingredients (APIs) for clinical trials and commercial drugs.
How to Spot the Best IPOs in 2025: A Beginner’s Guide
Sai Life Sciences adheres to rigorous global regulatory standards, including ICH Q7, 21 CFR Part 210 and 211, and EU GMPs. The company has undergone over 300 successful audits, including inspections by the USFDA and other international regulatory authorities, underscoring its commitment to quality and compliance.
Financially, the company has demonstrated consistent growth, with an annual revenue increase of 25-30% since 2005. Backed by venture capital investments, Sai Life Sciences continues to expand and innovate, strengthening its market position.
With a mission to advance healthcare by developing solutions for today’s incurable diseases, Sai Life Sciences remains a trusted partner for pharmaceutical and biotech companies worldwide. Its dedication to quality, innovation, and global health reinforces its role as a key contributor to tomorrow’s medical breakthroughs.
Sai Life Sciences IPO Company Financial Report
Based on the information provided in the DRHP, here is a summary of the key financial data for Sai Life Sciences Limited, with amounts presented in crores and lakhs:
| Financial Metric | FY 2024 | FY 2023 | Growth |
|---|---|---|---|
| Total Revenue | ₹1,494.27 crores | ₹1,241.31 crores* | 20.38% |
| Net Profit | ₹82.81 crores | ₹9.99 crores* | 729% |
| EBITDA Margin | 20.48% | Not provided | – |
| Return on Net Worth (RoNW) | 8.50% | Not provided | – |
*Calculated based on the given growth percentagesBalance Sheet Highlights (as of March 31, 2024):
| Metric | Amount |
|---|---|
| Total Assets | ₹2.07 crores |
| Total Equity | ₹(1.43) crores |
| Current Liabilities | ₹3.50 crores |
Cash Flow Statement (for the year ended March 31, 2024):
| Metric | Amount |
|---|---|
| Net Cash Generated from Operating Activities | ₹1.77 crores |
| Cash and Cash Equivalents at the End of the Year | ₹2.07 crores |
